A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction in patients with multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO)

Trial Profile

A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction in patients with multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO)

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis; Ophthalmoplegia
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jun 2017 Primary endpoint has been met. (FPA (first-pass amplitude)), according to results presented at the 3rd Congress of the European Academy of Neurology.
    • 27 Jun 2017 Results presented at the 3rd Congress of the European Academy of Neurology.
    • 18 Mar 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top